Meeting
2020 ASCO Virtual Scientific Program
Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
Authors
Shiao-Pei S. Weathers
The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX
Shiao-Pei S. Weathers , Carlos Kamiya-Matsuoka , Rebecca A. Harrison , Diane D. Liu , Shannon Dervin , Cindy Yun , Monica Elena Loghin , Marta Penas-Prado , Nazanin Majd , W. K. Alfred Yung , Barbara Jane O'Brien , John Frederick De Groot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03174197
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2511)
DOI
10.1200/JCO.2020.38.15_suppl.2511
Abstract #
2511
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon
Poster
2016 ASCO Annual Meeting
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2013 ASCO Annual Meeting
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation.
First Author: Jeffrey J. Raizer